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Abstract
Background: The aging kidney is marked by a chronic inflammation, which may exacerbate the progression of
renal dysfunction, as well as increase the susceptibility to acute injury. The identification of strategies to alleviate
inflammation may have translational impact to attenuate kidney disease.
Methods: We tested the potential of ashwaganda, sutherlandia and elderberry on tumor necrosis factor-α (TNF-α)
and lipopolysaccharide (LPS) induced chemokine (CCL2 and CCL5) expression in vitro.
Results: Elderberry water-soluble extract (WSE) was pro-inflammatory, while sutherlandia WSE only partially
attenuated the TNF-α-induced changes in CCL5. However, ashwaganda WSE completely prevented TNF-α-induced
increases in CCL5, while attenuating the increase in CCL2 expression and NF-κB activation. The same pattern of
ashwagandha protection was seen using LPS as the pro-inflammatory stimuli.
Conclusions: Taken together, these results demonstrate the ashwaganda WSE as a valid candidate for evaluation of
therapeutic potential for the treatment of chronic renal dysfunction.
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Background
Inflammation is a key component of the aging kidney
[1]; in both human [2, 3] and animal studies from our la-
boratory [4], it has been shown that a significant number
of genes whose expression is increased in aging are pro-
inflammatory. The kidney may be uniquely sensitive to
inflammation as it is a source for cytokine and chemo-
kine synthesis within the tubular epithelium [5], and due
to the high blood flow, it is continually exposed to circu-
lating pro-inflammatory mediators. There are significant
data linking inflammation to the loss of renal function
[6, 7]; the pro-inflammatory environment may also be
one of the mechanisms contributing to the increased se-
verity of acute injury in the aging kidney [8].
Fibrosis is an accumulation of matrix, predominantly
collagen, which is associated with loss of organ function
as normal tissue is replaced by scar tissue [9]. The
kidney is a prototypical example of an organ in which
progressive fibrosis leads to organ failure [10, 11]. A sig-
naling pathway that links inflammation and fibrosis in
the kidney is NF-κB. This transcription factor has a
long-recognized role as a pro-inflammatory mediator
[12, 13]. A number of stimuli induce NF-κB activity in
the kidney, including TNF [14] and angiotensin II [15] –
both of which are associated with chronic kidney disease
(CKD) [16, 17]. The list of NF-κB target genes is lengthy
but includes CCL2 and CCL5 (RANTES) [18, 19].
CCL5 is a chemoattractant for monocytes [20]; CCR1
and CCR5 are receptors for CCL5 [21]. A number of
studies now link CCL5, and other chemokines, including
CCL21 and its receptor CCR7, to renal fibrosis. There is
a parallel increase in the gene expression of CCL5 and
collagen 1α1 in a mouse model of progressive fibrosis
[22]. In a rat model of CKD, attenuation of inflammation
is associated with decreased CCL5 expression and re-
duced fibrosis [23]. A CCR1 antagonist (BX471) is asso-
ciated with reduction in fibrosis in multiple animal
models [24, 25]. CCL2 (monocyte chemotactic protein-1;
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MCP-1) is a C-C chemokine that is a ligand for the CCR2
receptor and is a potent chemoattractant for leukocytes, T
lymphocytes and NK (natural killer) cells [26]. Elevated
urinary CCL2 is associated with the development of fibro-
sis in human renal allografts and may be a poor predictor
of outcome [27, 28]. Thus, elevation of CCL2 and CCL5
may contribute the progressive fibrosis important in CKD.
Published data demonstrates that sutherlandia [29]
and elderberry [30, 31] have anti-inflammatory effects. It
is unclear as to whether these effects extend to renopro-
tection and, in fact, an elderberry-rich extract enriched
in anthocyanins did not improve renal function in a small
clinical trial of postmenopausal women [32]. In contrast,
ashwagandha (Withania somnifera) has been demon-
strated to be renoprotective via both antioxidant [33–35]
and anti-inflammatory effects [36]. The current studies
were designed to screen water-soluble extracts of ashwa-
ganda, sutherlandia and elderberry for anti-inflammatory
effects in renal epithelial cells.
Methods
Cell culture
NRK-52E cells (ATCC #CRL-1571) were grown in Dul-
becco’s modified eagle medium F-12 (DMEM/F12, 1:1)
without phenol red, but with L-glutamine and 15 mM
HEPES (Gibco #11039-021). The growth media also
contained 5 % fetal bovine serum (FBS; Atlanta Biolo-
gicals #S11150), 50 U/ml penicillin, and 50 mg/ml
streptomycin (Gibco #15140-122). A NRK-52E:NF-κB
reporter cell line was generated by stably transposing the
insulated NF-κB pathway reporter DNA [37] into the
chromatin of NRK-52E cells. The stable transfects were
selected in DMEM/F12 containing 5 % FBS, and 1 μg/ml
puromycin dihydrochloride (Sigma #P9620-10 ml). Both
cell types were cultured at 37 °C in 5 % CO2. Cells were
washed with 1X Dulbecco’s phosphate buffered saline
(DPBS; Gibco #14190-144), harvested with TrypLE Ex-
press (Gibco #12604-021), and centrifuged at 1,500xrpm
for 5 min at room temperature (RT).
Dosing
An aqueous extract of Sutherlandia frutescens was pre-
pared using the method described by Fernandes [38].
Briefly, 10 g of S. frutescens (ground powder of vegeta-
tive parts of S. frutescens purchased from Big Tree
Nutraceutical, Fish Hoek, South Africa) was added to
250 mL of boiling water. This mixture was kept in a
100 °C water bath for 1 h, with stirring every 10 min.
This mixture was allowed to cool overnight, in the dark.
The decoction was transferred into 50 mL sterilized cen-
trifuge tubes, and centrifuged at 2000×g for 20 min. The
supernatant was sterile-filtered using a 0.2 μm nylon fil-
ter (Fisher Scientific, Pittsburgh, PA, USA), and then
stored in 1.0 mL aliquots at −80 °C until used. The
product identity was confirmed using HPLC/ELSD and
HPLC/UV [39], which determined that the S. frutescens
used in this study contained 3.3 % (w/w) of sutherlandio-
side B, a specific biomarker of this medicinal plant [39, 40].
The Ashwagandha used for these experiments was ob-
tained from a commercial supplement (Now Foods,
Bloomingdale, IL, USA). Each capsule contained 450 mg
of a standardized extract containing a minimum of 2.5 %
total withanolides. The contents of several capsules were
weighed and dissolved in endotoxin-free, double-distilled
water at a 1:10 ratio (wt/vol). After vigorous mixing this
solution was allowed to sit overnight in the dark. The
following morning the mixture was vigorously mixed
again for 1 min, then non-soluble components were re-
moved by centrifugation (2000×g for 20 min). The
supernatant was sterile-filtered using a 0.2 μm nylon fil-
ter, and then stored in 1.0 mL aliquots at −80 °C until
used.
The elderberry juice used in these experiments was
obtained from elderberries harvested from North Ameri-
can varieties (Sambucus nigra, L. subsp. canadensis (L.
Bolli) near the peak of ripeness and immediately frozen.
Andrew L. Thomas (University of Misosuri) collected
the specimens from Eridu Farm, Hartsburg (Boone
County), MO, in full bloom on June 7, 2012. Location
38.710512 lat., −92.316186 long. A voucher specimen (A.
Thomas 120) from the field was preserved at the Univer-
sity of Missouri (UMO) [41]. While frozen the berries
were manually separated from stems, leaves, insects, and
other debris. Berries were thawed, juiced, then re-frozen.
At a later time, the frozen juice was thawed, centrifuged
(1000×g for 30 min), then the clarified juice was filtered
through a 0.2 μm sterile, pyrogen-free nylon filter
(Fisher Scientific, Inc.) and stored at −80 °C in 100 μL
aliquots. Just prior to addition to cell culture medium,
the frozen, sterile-filtered juice was thawed and diluted
1000-fold so as to supply a final concentration of ~100
μg of juice solids/mL.
The presence and concentration of endotoxin in each
of the extracts was quantified using the recombinant fac-
tor C endotoxin detection assay (Lonza Walkersville,
Inc., Cat. 50-658U, Walkersville, MD, USA) following
the instructions provided by the manufacturer. The
principle of this kit is that the recombinant Factor C is
activated by endotoxin binding, and the active moiety
created then acts to cleave a synthetic substrate resulting
in the generation of a fluorogenic compound. The high-
est concentration of endotoxin was found in the S. fru-
tescens (i.e., ~0.8 ng LPS equivalents/mL), while the
Ashwagandha extract and elderberry juice contained
0.004 and <0.001 ng of LPS equivalents/mL, respectively.
Recombinant Human Tumor Necrosis Factor alpha 1α
(TNF-α; #rhtnf-α) and standard lipopolysaccharide from
E. coli 0111:B4 strain- TLR4 ligand (LPS; #tlrl-eblps)
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were purchased from Invivogen. NRK-52E cells were
plated at a density of 120,000 cells/well in 6-well plates
and left to grow to confluency overnight. Cells were
washed with 1X DPBS and then treated with water or
botanical extract (1:100 dilution) for 24 h. Wells were
washed and then treated with water, TNF-α or LPS, bo-
tanical extract, or a combination of TNF-α or LPS plus
botanical extract for an additional 24 h. After 48 h treat-
ment, cells were harvested for RNA extraction.
NF−κB activity assay
NRK-52E:NF-κB cells were plated at a density of 100,000
cells/well in 12-well plates and left to grow to confluency
overnight. They were dosed as described above. Media
was removed and cells were washed twice with 1X
DPBS. Reporter lysis buffer was added to each well and
the plates were allowed to rock for 15 min at RT,
followed by a freeze/thaw cycle for 30 min at −80 °C and
30 min rocking at RT. Cell lysates were collected and
centrifuged for 15 s. Lysates were transferred to a new
tube and assayed for NF-κB green fluorescent protein
(GFP)/luciferase activity using the Luciferase Assay Sys-
tem kit (#E4030) from Promega. Briefly, 100 μl of lysate
was placed into each well of a 96-well flat bottom,
opaque white plate. The fluorescence of samples was
read for GFP expression at 485/20 nm excitation and
528/20 nm emission wavelengths. Then the luciferase
assay reagent was added to each well and the lumines-
cence of the wells was read for luciferase expression on
a Synergy HT plate reader using Gen5 (version 1.11)
software from Bio-TEK. NF-κB activation is expressed as
the individual luciferase/GFP values divided by the aver-
age control luciferase/GFP value.
Real-time PCR
RNA was extracted from the cells using the NucleoSpin
RNA kit (Macherey-Nagel #740955.50), with on-column
DNase digestion. RNA was quantified by a spectro-
photometric read using the Nanodrop 2000c (Thermo
Scientific). cDNA was made from the quantified RNA
using the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems #4368814), including a RNase
inhibition step (Applied Biosystems #N8080119). Real-
Time PCR was performed in duplicate using 200 ng
cDNA/reaction in conjunction with Taqman assays (Ap-
plied Biosystems) using TaqProbe 2X qPCR Multiplex
Master Mix (Bullseye #BEQPCR-PM) on the CFX96
Touch system (Bio-Rad). The following cycling condi-
tions were followed: 95 °C for 20 s, then 95 °C for 1 s
and 60 °C for 20 s repeated 40 times. TaqMan primer
sets (Life Technologies) were used to determine Chemo-
kine (C-C motif ) ligand 2 (CCL2; RN00580555_m1) and
chemokine (C-C motif ) ligand 5 (CCL5; Rn00579590_
m1). The Pfaffl method was used to determine relative
quantitation, normalizing the data to cancer susceptibil-
ity candidate gene 3 (Casc3; RN00595941_m1) [42].
Statistics
Data is expressed as the mean +/- standard error. A two-
tailed t-test, assuming two-sample equal variance, was
used to determine significance. P-values of <0.05 were
considered statistically significant.
Results
Initial experiments were designed to determine an opti-
mal concentration of TNF-α to induce CCL5 expression;
published studies have shown that NRK-52E cells re-
spond to 10 ng/ml for 6–48 h [43, 44]. In our experi-
ments, higher concentrations (100 or 500 ng/ml) failed
to substantially enhance CCL5 gene expression, while re-
sults with 50 ng/ml were highly variable (Fig. 1). A con-
centration of 10 ng/ml for 24 h induced an approximate
10-fold increase in CCL5 gene expression that was not
seen at early (3 or 6 h) timepoints (Fig. 1). We then
screened water-soluble extracts of ashwagandha, suther-
landia, or elderberry at a dilution of 1:100. We used two
approaches – cells were exposed to the botanical ex-
tracts for 24 h prior to 10 ng/ml TNF-α challenge alone
or in the continued presence of the botanical for 24 h.
Interestingly, elderberry alone induced CCL5 expression
to the extent of TNF-α, while pretreatment and co-
treatment with sutherlandia attenuated TNF-α-induced
CCL5 expression (Fig. 2). Ashwagandha, however, com-
pletely ablated the induction of CCL5 by TNF-α when
cells were pretreated or cotreated (Fig. 2). Interestingly,
both ashwaganda and sutherlandia also inhibited basal
CCL5 gene expression in NRK-52E cells.
In Fig. 3, the same treatment regimens (pretreatment
and pretreatment/cotreatment) were used with the ashwa-
gandha (Ash) extracts. Pre-treatment with Ash inhibited
both CCL2 and CCL5 expression induced by TNF-α. In
the case of CCL2, which was induced to a higher extent
than CCL5 by TNF-α, the protective effect was partial,
but not complete (Fig. 3). TNF-α did not increase expres-
sion of CCL17, 19, or 21, or expression of COX-2 (data
not shown). In addition, the pretreatment/co-treatment
approach was most effective at attenuating CCL2 expres-
sion. Given that TNF-α induces NF-κB activation [14],
and that NF-κB regulates CCL2 and 5 expression [18, 19],
we used an NF-κB reporter cell line to investigate the po-
tential of Ash to inhibit TNF-α-induced NF-κB activation.
While pretreatment with Ash partially attenuated NF-kB
activation following TNF-α challenge, the pretreatment/
cotreatment regimen completely blocked TNF-α-induced
NF-κB activation (Fig. 3). Ashwagandha did not, however,
affect basal NF-kB activity parallel to the reduction in
basal CCL5 expression.
Grunz-Borgmann et al. BMC Complementary and Alternative Medicine  (2015) 15:434 Page 3 of 8
To ensure that the effects of ashwagandha were not
limited to TNF-α, we then challenged cells with LPS
using the same approach. NRK-52E cells have been chal-
lenged with 10–100 ng/ml LPS for 24 h [45]. We chose
to use concentrations at the lower end of this range; 2
or 10 ng/ml LPS is associated with a robust increase in
both CCL2 and CCL5 gene expression at 24 h (Fig. 4).
Interestingly, the response is not dose-dependent in that
the response was greater using 2 ng/ml. Pretreatment
with Ash attenuated LPS-induced CCL2 and prevented
CCL5 expression, while the pretreatment/cotreatment
strategy further attenuated CCL2 expression and CCL5
expression was completely inhibited (Fig. 4). The pre-
treatment with Ash attenuated LPS-induced NF-κB activ-
ity, while the pretreatment/cotreatment strategy prevented
the effect (Fig. 4).
Discussion
The identification of specific strategies to slow the pro-
gression of chronic renal dysfunction, or to attenuate
acute injury, has been a frustratingly slow process. Given
the role of inflammation in injury and progression to
dysfunction via pro-fibrogenic mechanisms, strategies to
attenuate inflammation are promising therapeutics.
There are a number of studies suggesting that botanicals
are anti-inflammatory [29–31, 36]; however, the molecular
Fig. 2 Ashwagandha prevents TNF-α-induced CCL5 gene expression. Confluent NRK-52E cells were treated for 24 h with water-soluble extracts of
ashwagandha, sutherlandia or elderberry (1:100). After 24 h, cells were challenged with 10 ng/ml of TNF-α for 24 h alone or in the presence of the
botanical extract. CCL5 gene expression was determined by qPCR. Each data point represents the mean ± SD of three replicate cultures, * indicates a
significant difference as compared to control (no botanical, no TNF-α), # indicates a significant difference from TNF-α-challenged cultures
Fig. 1 TNF-α induces CCL5 expression in NRK-52E cells. Confluent cells were challenged with varying concentrations of TNF-α for 3–24 h; CCL5
expression was assessed by qPCR. Each data point represents the mean ± SD of three replicate cultures
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pathways targeted by many of these remains poorly de-
fined. In our studies, we developed an in vitro model to
screen botanical extracts for anti-inflammatory cells in a
rat proximal tubular epithelial cell line, NRK-52E, since
the proximal tubular epithelium is both a source [5] and
target of inflammation in the kidney. In these studies, cells
were challenged with a pro-inflammatory stimuli either
after exposure to the botanical, or simultaneously with the
botanical.
Interestingly, an elderberry extract, which has reported
anti-inflammatory effects [46], induced CCL5 expression
to a similar extent as TNF-α in our model. A sutherlan-
dia extract partially attenuated TNF-α-induced CCL5
gene expression, but ashwaganda completely inhibited
the TNF-α effect on CCL5 expression. This anti-
inflammatory effect of ashwagandha is further supported
by our findings that the extract attenuates TNF-α and
LPS-induced CCL2 expression and NF-κB activation, and
inhibited LPS-induced CCL5 expression. Ashwagandha
has been reported to be renoprotective in several studies,
mainly as an antioxidant. Ashwagandha is renoprotec-
tive against bromobenzene-induced nephrotoxicity
[35], gentamicin-induced nephrotoxicity [34, 47] and
dehydration-induced oxidative stress [33]. Mechanis-
tically, it has a positive effect on glutathione peroxid-
ase, superoxide dismutase, and catalase levels [34].
An interesting finding was the ashwagandha decreased
basal expression of CCL5, but did not affect basal CCL2
expression or NF-kB activation. The impact of ashwa-
ganda on CCL2 expression paralleled the effects on NF-
kB activation, i.e. attenuated TNF-α- or LPS-induced
increases. These data suggest that ashwagandha affects
Fig. 3 Ashwagandha attenuated TNF-α-induced CCL2 gene expression and NF-κB activation. Confluent NRK-52E cells were treated for 24 h with
water-soluble extracts of ashwagandha (Ash; 1:100). After 24 h, cells were challenged with 10 ng/ml of TNF-α for 24 h alone or in the presence of
the ashwaganda extract. CCL2 and 5 gene expression was determined by qPCR (top) while NF-κB activation was assessed using a reporter cell line
(bottom). Each data point represents the mean ± SD of three replicate cultures, repeated twice, * indicates a significant difference as compared to
control (no botanical, no TNF-α), # indicates a significant difference from TNF-α-challenged cultures
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other signaling pathways which regulate CCL5 expres-
sion; candidates include the p38 MAPK pathway
which has been shown to inhibit CCL5 in smooth
muscle cells [48]. Withaferin A, a bioactive compo-
nent of ashwagandha [49], has been shown to in-
crease p38 activity [50], as has another component of
ashwagandha, withanolide D [51].
There are a number of papers demonstrating that
withaferin A inhibits NF-κB signaling [52, 53]. Witha-
ferin A also inhibits NF-κB activation by inhibiting IKKb
catalytic activity [54]. In addition, there is data demon-
strating that withaferin A inhbits TNF-α-induced effects
in endothelial cells [55]. We examined withaferin A in
our model system, however, at concentrations (1 μM)
and timepoints (2 h) previously reported [54, 55], witha-
ferin A induced substantial cytotoxicity in our cells (data
not shown). As such, withaferin A induces apoptosis in a
number of cell types [56, 57] putatively via down regula-
tion of JAK/STAT3 in cancer cells [58]. Given that witha-
ferin A is not readily-water soluble and that it was
cytotoxic, our data suggest that withaferin A is not solely
responsible for anti-inflammatory effects of ashwagandha.
Future studies will focus on the pathway by which ashwa-
ganda regulates both basal- and stimulus-induced chemo-
kine expression. In addition, the confirmation of these
findings in in vivo models of progressive renal injury
and dysfunction represents an important progression
of botanical-based renoprotection research.
Fig. 4 Ashwagandha attenuated LPS-induced CCL2 and CCL5 gene expression and NF-κB activation. Confluent NRK-52E cells were treated for
24 h with water-soluble extracts of ashwagandha (Ash; 1:100). After 24 h, cells were challenged with 2 or 10 ng/ml of LPS for 24 h alone or in the
presence of the ashwaganda extract. CCL2 and 5 gene expression was determined by qPCR (top) while NF-κB activation was assessed using a
reporter cell line (bottom). Each data point represents the mean ± SD of three replicate cultures, repeated twice, * indicates a significant difference
as compared to control (no botanical, no LPS), # indicates a significant difference from LPS-challenged cultures
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Conclusions
A water-soluble extract of Ashwagandha has anti-
inflammatory effects, specifically reducing gene expresi-
son of CCL2 and CCL5 in response to TNFα or LPS
stimulation. This may be mediated, in part, via a reduc-
tion in NF-κB activity. These data suggest that Ashwa-
gandha may represent a botanical approach for the
management of renal dysfunction.
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